Shield Therapeutics plc
STX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £32 | £21 | £14 | £50 |
| - Cash | £11 | £6 | £6 | £11 |
| + Debt | £27 | £21 | £16 | £16 |
| Enterprise Value | £49 | £37 | £23 | £55 |
| Revenue | £17 | £16 | £10 | £7 |
| % Growth | 6.5% | 61.9% | 37.3% | – |
| Gross Profit | £8 | £7 | £4 | £1 |
| % Margin | 46.1% | 43.1% | 45% | 14.1% |
| EBITDA | -£4 | -£6 | -£10 | -£16 |
| % Margin | -22.9% | -39.5% | -109.2% | -223.9% |
| Net Income | -£7 | -£9 | -£12 | -£17 |
| % Margin | -44.5% | -58.4% | -127.6% | -236.4% |
| EPS Diluted | -0.007 | -0.012 | -0.016 | -0.022 |
| % Growth | 38.8% | 25.6% | 29.7% | – |
| Operating Cash Flow | -£4 | -£4 | -£3 | -£14 |
| Capital Expenditures | -£0 | -£0 | -£1 | -£1 |
| Free Cash Flow | -£4 | -£4 | -£4 | -£15 |